Cancer Communications
indexed by SCI
BMC

[ Special series on lung cancer 2 ]
doi: 10.1186/s40880-016-0127-x
Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period
Fumio Asano, Keisuke Watanabe, Masaharu Shinkai, Yoshitaka Tei, Kei Mishina, Mikiko Tanabe, Hiroshi Ishii, Masahiro Shinoda, Tadasuke Shimokawaji, Makoto Kudo and Takeshi Kaneko
Respiratory Disease Center, Yokohama City University Medical Center
[Abstract] Lambert–Eaton myasthenic syndrome (LEMS) is a paraneoplastic syndrome and only 3% of small cell lung carcinoma (SCLC) patients have LEMS. Moreover, the recurrence of SCLC after a disease-free survival (DFS) of more than 10 years is rare. We report a patient who had a recurrence of both SCLC and LEMS after a 13-year DFS period. A 69-year-old man was diagnosed with LEMS and SCLC (cT0N2M0, stage IIIA) 13 years ago. Chemoradiotherapy was performed and a complete response was achieved. With anticancer treatment, the LEMS symptoms was alleviated. At the age of 82 years, gait disturbance appeared followed by left supraclavicular lymphadenopathy and further examination revealed the recurrence of SCLC. Careful screening for the recurrence of SCLC might be needed when the patient has recurrent or secondary paraneoplastic neurological syndrome even after a long DFS period.
Chinese Journal of Cancer 2016, Volume: 35, Issue 11
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)

[Google Scholar]


[ More articles of the special series on lung cancer 2 ]


Cite this article

Fumio Asano, Keisuke Watanabe, Masaharu Shinkai, Yoshitaka Tei, Kei Mishina, Mikiko Tanabe, Hiroshi Ishii, Masahiro Shinoda, Tadasuke Shimokawaji, Makoto Kudo and Takeshi Kaneko. Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period. Chin J Cancer. 2016, 35:63. doi:10.1186/s40880-016-0127-x


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China